These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8809866)

  • 21. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid-induced preconditioning: recent advances and future perspectives.
    Peart JN; Gross ER; Gross GJ
    Vascul Pharmacol; 2005; 42(5-6):211-8. PubMed ID: 15922254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo.
    De Minicis S; Candelaresi C; Marzioni M; Saccomano S; Roskams T; Casini A; Risaliti A; Salzano R; Cautero N; di Francesco F; Benedetti A; Svegliati-Baroni G
    Gut; 2008 Mar; 57(3):352-64. PubMed ID: 17989109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous opioid peptides system in haemorrhagic shock--central cardiovascular regulation.
    Jochem J; Jośko J; Gwóźdź B
    Med Sci Monit; 2001; 7(3):545-9. PubMed ID: 11386040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair.
    Sharma A; Sharma HS
    Int Rev Neurobiol; 2012; 102():23-45. PubMed ID: 22748825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous opioid systems: current concepts and clinical correlations.
    Benarroch EE
    Neurology; 2012 Aug; 79(8):807-14. PubMed ID: 22915176
    [No Abstract]   [Full Text] [Related]  

  • 27. Epilepsy, CNS viral injury and dynorphin.
    Solbrig MV; Koob GF
    Trends Pharmacol Sci; 2004 Feb; 25(2):98-104. PubMed ID: 15102496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of melanocortins in CNS injury.
    Sharma HS; Lundstedt T; Flärdh M; Skottner A; Wiklund L
    Curr Pharm Des; 2007; 13(19):1929-41. PubMed ID: 17627526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arbiters of endogenous opioid analgesia: role of CNS estrogenic and glutamatergic systems.
    Gintzler AR; Liu NJ
    Transl Res; 2021 Aug; 234():31-42. PubMed ID: 33567346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progesterone receptor-mediated actions and the treatment of central nervous system disorders: An up-date of the known and the challenge of the unknown.
    González SL; Coronel MF; Raggio MC; Labombarda F
    Steroids; 2020 Jan; 153():108525. PubMed ID: 31634489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Endogenous Opioid System: Role and Dysfunction Caused by Opioid Therapy.
    Toubia T; Khalife T
    Clin Obstet Gynecol; 2019 Mar; 62(1):3-10. PubMed ID: 30398979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cnidarian peptide neurotoxins: a new source of various ion channel modulators or blockers against central nervous systems disease.
    Liao Q; Feng Y; Yang B; Lee SM
    Drug Discov Today; 2019 Jan; 24(1):189-197. PubMed ID: 30165198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroprotective effects of peptides bioregulators in people of various age].
    Umnov RS; Lin'kova NS; Khavinson VKh
    Adv Gerontol; 2013; 26(4):671-8. PubMed ID: 24738258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subarachnoid pharmacodialysis for central nervous system disorders.
    Kral JG; Ludvig N
    Med Hypotheses; 2013 Feb; 80(2):105-11. PubMed ID: 23127501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of agmatine for CNS disorders.
    Neis VB; Rosa PB; Olescowicz G; Rodrigues ALS
    Neurochem Int; 2017 Sep; 108():318-331. PubMed ID: 28522414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of neuroprotective compounds in the pharmaceutical industry: where are we, and where are we going?
    Santilli N
    Prog Brain Res; 2002; 135():497-507. PubMed ID: 12143368
    [No Abstract]   [Full Text] [Related]  

  • 37. D-Arginine as a neuroprotective amino acid: promising outcomes for neurological diseases.
    Canteros MG
    Drug Discov Today; 2014 May; 19(5):627-36. PubMed ID: 24252866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Endogenous Opioid System as a Pathway of Positive Emotions.
    Barenz J; O'Donnell M; Smith J
    Adv Neurobiol; 2024; 35():241-250. PubMed ID: 38874726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotoxic effect of nalufin on the histology, ultrastructure, cell cycle and apoptosis of the developing chick embryo and its amelioration by selenium.
    Atallah MN; Badawy GM; El-Garawani IM; Abdallah FS; El-Borm HT
    Food Chem Toxicol; 2021 Dec; 158():112693. PubMed ID: 34801652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathways of neurotoxicity and innovative neuroprotective strategies. Preface.
    Patterson TA; Wood WG; Andrews RJ; Slikker W
    Mol Neurobiol; 2013 Oct; 48(2):271-3. PubMed ID: 23884619
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.